Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
Conmed Corporation (CNMD) is a globally recognized medical technology company headquartered in Utica, New York. Specializing in the design, manufacturing, and distribution of surgical and patient monitoring products, Conmed plays a pivotal role in advancing healthcare outcomes. The company’s mission is to improve the quality of healthcare through innovative and high-quality medical solutions that empower healthcare professionals to deliver superior patient care.
Core Business Areas
Conmed operates across several key medical specialties, including:
- Orthopedics: Providing advanced surgical tools and implants for sports medicine and other orthopedic procedures.
- General Surgery: Offering devices and instruments designed to enhance surgical precision and efficiency.
- Gynecology: Delivering specialized products tailored for women’s health and minimally invasive procedures.
- Gastroenterology and Pulmonology: Supplying innovative solutions for diagnostic and therapeutic interventions in the digestive and respiratory systems.
- Anesthesiology: Developing patient monitoring systems that ensure safety and reliability during surgical procedures.
Global Reach and Market Presence
With a strong presence in the United States, Europe, the Middle East, Africa, Asia Pacific, and North America, Conmed serves a diverse range of healthcare providers worldwide. Its products are trusted by surgeons and medical professionals across multiple specialties, showcasing its commitment to enhancing patient outcomes on a global scale.
Business Model and Revenue Generation
Conmed generates revenue through the direct sale of its medical devices and equipment to hospitals, surgical centers, and healthcare institutions. By focusing on customer satisfaction and building long-term partnerships, the company ensures a steady demand for its innovative solutions. Its emphasis on research and development enables the continuous introduction of cutting-edge technologies that address evolving medical needs.
Competitive Landscape
Operating within the highly competitive medical technology industry, Conmed faces competition from major players such as Medtronic, Stryker, and Johnson & Johnson. The company differentiates itself through its customer-centric approach, commitment to quality, and targeted focus on specific medical specialties. Its ability to innovate and adapt to changing healthcare trends further strengthens its market position.
Commitment to Excellence
Conmed's dedication to improving healthcare extends beyond its products. The company prioritizes thoughtful leadership, employee development, and community engagement. By fostering a culture of innovation and responsibility, Conmed reinforces its role as a trusted partner in the global medical community.
Conclusion
Conmed Corporation exemplifies the integration of cutting-edge technology and a customer-first philosophy within the medical device industry. Its focus on enhancing clinical outcomes, coupled with a robust global presence, positions the company as a key contributor to the advancement of healthcare worldwide. By continuously innovating and maintaining high standards of quality, Conmed remains a vital player in the ever-evolving medical technology landscape.
CONMED Corporation (NYSE: CNMD) reported a strong financial performance for Q2 2021, with sales reaching $255.2 million, a 61.7% increase year over year. Domestic revenue surged 64.2%, while international sales climbed 58.6%. Diluted EPS was $0.41, up from a loss of $0.96 in Q2 2020. The company raised its full-year revenue guidance to between $1.015 billion and $1.035 billion and adjusted EPS guidance to $3.15 to $3.25, reflecting confidence in ongoing operational improvements and market recovery.
CONMED Corporation (NYSE: CNMD) is set to report its Q2 2021 financial results on July 28, 2021, after market close. A conference call will be held at 4:30 p.m. ET to discuss the results. Interested parties can join the call by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) with passcode 7138188. The call will also be available via webcast on the CONMED website, and a recording will be accessible from 7:30 p.m. ET on the same day until August 4, 2021.
CONMED Corporation (NYSE: CNMD) declared a quarterly cash dividend of $0.20 per share. This dividend is payable on July 6, 2021, to shareholders of record as of June 15, 2021. CONMED specializes in medical technology, offering surgical devices for minimally invasive procedures across various specialties, including orthopedics and general surgery. For additional details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) reported first-quarter 2021 financial results, highlighting a sales increase of 8.7% year-over-year to $232.7 million. Domestic revenue rose 4.3%, while international revenue surged 14.3%. Diluted EPS rose 55.0% to $0.31. The company enhanced its 2021 revenue guidance to between $1.0 billion and $1.03 billion, up from $975 million to $1.02 billion. Adjusted diluted EPS guidance is now $3.05 to $3.20, improved from $2.85 to $3.05.
CONMED Corporation (NYSE: CNMD) will report its first-quarter 2021 financial results after market close on April 28, 2021. Management will host a conference call at 4:30 p.m. ET the same day to discuss the results. Investors can participate by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) using passcode 1487002. The call will also be webcast on the company's website, with a replay available one hour post-call. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) has announced its Annual Meeting of Stockholders, to be held virtually on May 19, 2021, at 1:30 p.m. ET. Shareholders of record by March 29, 2021, are eligible to vote. CONMED specializes in medical technology, particularly surgical devices for minimally invasive procedures across various specialties. The company cautions that forward-looking statements may be affected by uncertainties, including the impact of COVID-19 on surgical volumes and supply chains, among other risk factors.
CONMED Corporation (NYSE: CNMD) announced participation in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2021, at 11:30 a.m. ET. The session will feature Chair and CEO Curt R. Hartman and CFO Todd W. Garner. Investors can access the live webcast via the Company’s website at www.conmed.com, which will be available for replay post-event. CONMED specializes in minimally invasive surgical devices used across various medical specialties.
CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share, payable on April 5, 2021 to shareholders on record as of March 15, 2021.
CONMED is a medical technology company that provides surgical devices for minimally invasive procedures, serving various specialties including orthopedics and neurosurgery. The announcement reflects the company's ongoing commitment to returning value to shareholders.
CONMED Corporation (NYSE: CNMD) announced participation of Curt R. Hartman, Chair of the Board and CEO, alongside Todd W. Garner, CFO, in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference. The event is scheduled for 9:20 a.m. ET on February 25, 2021.
The live webcast will be available in the ‘Investors’ section of their website, and a replay will be accessible post-event. CONMED is a provider of surgical devices for minimally invasive procedures across various specialties, including orthopedics and neurosurgery.
CONMED Corporation (NYSE: CNMD) reported Q4 2020 sales of $252.8 million, down 4.5% year-over-year, with domestic revenue decreasing 0.7% and international revenue falling 9.1%. Diluted EPS rose to $0.81 from $0.49 in Q4 2019, while adjusted EPS decreased from $0.90 to $0.84. For the full year, sales were $862.5 million, a 9.7% decline, and diluted EPS was $0.32 versus $0.97 in 2019. The company expects 2021 revenue between $975 million and $1.02 billion, with adjusted EPS forecasted at $2.85 to $3.05.
FAQ
What is the current stock price of Conmed (CNMD)?
What is the market cap of Conmed (CNMD)?
What does Conmed Corporation specialize in?
What are the key medical specialties Conmed serves?
How does Conmed generate revenue?
What is Conmed's competitive advantage?
Where is Conmed Corporation headquartered?
What is Conmed's global presence?
What is Conmed's mission?
Who are Conmed's main competitors?
What industries does Conmed operate in?
How does Conmed contribute to healthcare innovation?
